Cancer Markers Associated With Occupational Exposure to Trichloroethylene
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00481611|
Recruitment Status : Completed
First Posted : June 4, 2007
Last Update Posted : May 17, 2018
- Trichloroethylene (TCE) is a solvent used in many medical and industrial processes.
- TCE is a carcinogen (causes cancer) in rats, but its carcinogenicity in humans is unclear. There is some evidence of increased liver and kidney cancers and of an association with non-Hodgkin lymphoma in studies of workers exposed to TCE.
- The carcinogenicity and regulation of TCE is a matter of continuing debate.
- To determine if TCE exposure is associated with higher levels of genetic aberrations in certain white blood cells called lymphocytes.
- To determine if TCE exposure affects lymphocyte subsets and levels of certain hormones called cytokines.
Eligibility: Workers exposed to two different levels of exposure to TCE and unexposed workers in Guangdong Province, China.
- 45 workers exposed to more than 25 parts per million (ppm) TCE, 30 workers exposed to from 10 to less than 25 ppm TCE and 45 unexposed workers will be enrolled.
- Subjects wear small instruments at work that measure chemicals in the air for 1 or 2 days during the 2-week study period. Exposed workers also wear several small skin patches on one of the two days.
- Subjects provide blood and urine samples.
- Subjects answer a questionnaire about work, smoking and drinking, use of medicines, medical history, general health, hobbies, and exposure to radiation and exposure to various substances at home.
|Condition or disease|
|Industrial Hygiene Epidemiology Neoplasms|
|Study Type :||Observational|
|Actual Enrollment :||125 participants|
|Official Title:||A Cross-Sectional Study of Occupational Exposure to Trichloroethylene, Chromosomal Aberrations, and Related Biomarkers in Guangdong, China|
|Study Start Date :||June 15, 2006|
- Hematotoxicity change [ Time Frame: 28 years ]
- Immune function [ Time Frame: 28 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00481611
|Guangdong National Poison Control Center (NPCC)|
|Principal Investigator:||Qing Lan, M.D.||National Cancer Institute (NCI)|